| Literature DB >> 22896003 |
Jessica L Allen1, Matthew S Fore, Jenna Wooten, Philip A Roehrs, Nazmim S Bhuiya, Todd Hoffert, Andrew Sharf, Allison M Deal, Paul Armistead, James Coghill, Don A Gabriel, Robert Irons, Amber Essenmacher, Thomas C Shea, Kristy Richards, Corey Cutler, Jerome Ritz, Jonathan Serody, Albert S Baldwin, Stefanie Sarantopoulos.
Abstract
Recent data reveal an important role for B cells in the pathogenesis of chronic GVHD (cGVHD). Patients with cGVHD have delayed B-cell reconstitution and elevated BAFF to B-cell ratios compared to patients without cGVHD. The mechanisms promoting and sustaining B-cell activation in this disease, however, remain unknown. As BAFF increases murine B-cell metabolism and survival and maintains autoreactive B-cell clones, we performed ex vivo analyses of peripheral B cells from 51 patients who either had or did not have active cGVHD and were greater than 1 year from the time of allogeneic hematopoietic stem cell transplantation. We found that B cells from patients with active cGVHD were in a heightened metabolic state and were resistant to apoptosis. Exogenous BAFF treatment amplified cell size and survival in B cells from these patients. We found significantly increased signaling through ERK and AKT that associated with decreased levels of proapoptotic Bim, suggesting a mechanistic link between elevated BAFF levels and aberrant B-cell survival. Thus, we identify a role for BAFF in the pathogenesis of cGVHD and define B-cell activation and survival pathways suitable for novel therapeutic development in cGVHD.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22896003 PMCID: PMC3448264 DOI: 10.1182/blood-2012-06-438911
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113